Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
4.
J Allergy Clin Immunol Pract ; 9(7): 2556-2561, 2021 07.
Article in English | MEDLINE | ID: covidwho-1193363

ABSTRACT

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents our greatest hope to combat the devastating coronavirus disease 2019 (COVID-19) pandemic. Amid ongoing global vaccination efforts, rare cases of severe allergic reactions to COVID-19 mRNA vaccines have received significant attention. Although the exact nature of these reactions may be heterogeneous, various approaches exist to engage with patients, communities, public health departments, primary care providers, and other clinicians in a multidisciplinary approach to advance population health. Whereas it is optimal for patients to receive COVID-19 vaccination as outlined in emergency use authorizations, second-dose deferral of mRNA vaccines may be a consideration within a shared decision-making paradigm of care in select circumstances characterized by high durable first-vaccine-dose protection and significant elevations of vaccine anaphylaxis risk. Still, the durability of protection afforded by a single dose of a COVID-19 mRNA vaccine is uncertain, and alternative approaches to complete vaccination, including precautionary use of a COVID-19 viral vector vaccine, also remain patient-preference-sensitive options. There is an urgent need to define correlates of COVID-19 immunity and the level of longer-term protection afforded by COVID-19 vaccination.


Subject(s)
Anaphylaxis , COVID-19 , COVID-19 Vaccines , Humans , RNA, Messenger , SARS-CoV-2 , Vaccination
6.
J Allergy Clin Immunol Pract ; 8(9): 2851-2857, 2020 10.
Article in English | MEDLINE | ID: covidwho-670976

ABSTRACT

The SARS-CoV2 pandemic has prompted a re-evaluation of our current practice of medicine. The seemingly abrupt worldwide spread of this disease resulted in immediate changes and a reduction in many allergy-focussed services and procedures. The reality of the long-term circulation of this virus in our communities requires us to evolve as a specialty. In this article, we outline current and future challenges in the management of food allergy in light of coronavirus disease 2019 (COVID-19). We focus on infant food allergy prevention, management of anaphylaxis, accurate diagnosis with oral food challenges, and active management of food allergy with oral immunotherapy. This article identifies the challenges of conflicting guidelines, shortcomings of acute management approaches, and inherent system deficiencies. We offer perspectives and strategies that can be implemented now, including an evaluation of virtual care and telemedicine for the management of food allergy. The use of a shared decision-making model results in novel approaches that can benefit our patients and our specialty for years to come. COVID-19 has forced us to re-evaluate our current way of thinking about food allergy management to better treat our patients.


Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Food Hypersensitivity/diagnosis , Food Hypersensitivity/drug therapy , Immunotherapy/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Telemedicine/methods , Anaphylaxis/complications , Anaphylaxis/drug therapy , COVID-19 , Food Hypersensitivity/complications , Humans , SARS-CoV-2
7.
J Allergy Clin Immunol Pract ; 8(9): 2845-2850, 2020 10.
Article in English | MEDLINE | ID: covidwho-718811

ABSTRACT

In the wake of the COVID-19 pandemic and massive disruptions to daily life in the spring of 2020, in May 2020, the Centers for Disease Control (CDC) released guidance recommendations for schools regarding how to have students attend while adhering to principles of how to reduce the risk of contracting SARS-CoV-2. As part of physical distancing measures, the CDC is recommending that schools who traditionally have had students eat in a cafeteria or common large space instead have children eat their lunch or other meals in the classroom at already physically distanced desks. This has sparked concern for the safety of food-allergic children attending school, and some question of how the new CDC recommendations can coexist with recommendations in the 2013 CDC Voluntary Guidelines on Managing Food Allergy in Schools as well as accommodations that students may be afforded through disability law that may have previously prohibited eating in the classroom. This expert consensus explores the issues related to evidence-based management of food allergy at school, the issues of managing the health of children attending school that are acutely posed by the constraints of an infectious pandemic, and how to harmonize these needs so that all children can attend school with minimal risk from both an infectious and allergic standpoint.


Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Epinephrine/therapeutic use , Food Hypersensitivity/drug therapy , Food Hypersensitivity/prevention & control , Inservice Training/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , School Health Services , Adolescent , Adrenergic alpha-Agonists/therapeutic use , Anaphylaxis , COVID-19 , Centers for Disease Control and Prevention, U.S. , Child , Educational Personnel/education , Humans , Practice Guidelines as Topic , SARS-CoV-2 , Schools , United States
SELECTION OF CITATIONS
SEARCH DETAIL